Background
The purpose of this study was to describe the initial experience with alemtuzumab as induction followed by steroid-free immunosuppression in kidney transplantation.
Methods
One hundred patients who received renal transplants from living and deceased donors were followed for a median period of 12 months (range 1 to 12). A 30-mg intravenous dose of Alemtuzumab was administered on the transplant day, preceded by a 500-mg methylprednisolone dose. Maintenance immunosuppression consisted in the use of a calcineurin inhibitor in association with mycophenolic acid. Maintenance C2 levels of cyclosporine were between 400 and 600 ng/dL; or of tacrolimus, between 4 and 7 ng/dL. Prophylaxis included valgancyclovir, trimethoprim-sulfamethoxasole, and nystatin. All patients were evaluated for acute rejection episodes, adverse events, or death.
Results
The cumulative incidences of acute rejection at 1, 3, 6, and 12 months were 0%, 4% (n 4), 5% (n 5), and 8% (n 8), respectively. Most episodes were Banff1a or b (88%). The infectious complication rate was 23%. There was no case of cytomegalovirus infection or posttransplant lymphoproliferative disease. Three patients died: one due to tuberculosis; one, sepsis; and one, an acute coronary event. No patient was lost to follow-up.
Conclusions
This study suggested the safety and efficacy of Campath-1H as an induction agent in renal transplant recipients.